Device Trial Radar · NCT05147571
RNS System NAUTILUS Study
Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Aug 9, 2022
Primary completion
Apr 4, 2025
Study completion Mar 31, 2026
Sponsor
- Lead sponsor
- NeuroPaceNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 7, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant idiopathic generalized epilepsy.
Conditions
- Epilepsy
- Idiopathic Generalized Epilepsy
- Generalized Tonic Clonic Seizure
Interventions
Responsive stimulationDevice
The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
Sham stimulationDevice
For those in the Sham Stimulation group, the RNS System will be set to detect abnormal activity but will not have responsive stimulation enabled. Both Sham and Active groups will undergo therapy testing at each appointment in order to maintain the blind.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 12-week post-operative serious device-related adverse event (SADE) rateTime frame: 84 days post-implant (12 weeks)
- Time to second generalized tonic-clonic (GTC) seizureTime frame: 9-month Effectiveness Evaluation Period
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Mayo Clinic - Arizona
Phoenix, Arizona
University of Colorado
Aurora, Colorado
20 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.